WEED, INC.
WEED, INC. (BUDZ): 3 pipeline candidates · ~0 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
0.3 months
D/E -1.62 · 0% dilution
Lead: Preclinical
3 candidates
N/A
0 buys · 6 sells (180d)
A transparent, data-derived signal for WEED, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.4M
Cash
$2K
Quarterly Burn
$58K
Runway
0.3 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| Cannabis Genomic Study | Preclinical |
| Cannabis Genomic Study (Sangre AT, LLC) | — |
| cannabis-derived compounds | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2023Institutional holders
1
Total value held
$4K
| Holder | Shares | Value |
|---|---|---|
| fisher asset management, llc | 74,111 | $4K |
Frequently asked questions
How many drug candidates are in WEED, INC.'s pipeline?
WEED, INC. (BUDZ) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is WEED, INC.'s lead drug candidate?
WEED, INC.'s most advanced tracked candidate is Cannabis Genomic Study (Preclinical) for New therapies for migraines/chronic pain, epilepsy, cancer, PTSD, chronic head injury, and others.
What is WEED, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, WEED, INC. has approximately 0.3 months of cash runway.
What is WEED, INC.'s market capitalization?
WEED, INC.'s market capitalization is approximately $4.4M.
Who is the CEO of WEED, INC.?
Mr. Glenn E. Martin is the chief executive officer of WEED, INC. (BUDZ).
Get the full picture on WEED, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.